Initial

KBRA Assigns Preliminary Ratings to FortiFi 2023-1, Series 2023-1

Retrieved on: 
Wednesday, May 17, 2023

KBRA assigns preliminary ratings to two classes of notes issued by FortiFi 2023-1, Series 2023-1 (“FortiFi 2023-1”, LLC.

Key Points: 
  • KBRA assigns preliminary ratings to two classes of notes issued by FortiFi 2023-1, Series 2023-1 (“FortiFi 2023-1”, LLC.
  • The notes are newly issued asset-backed securities backed by a portfolio of Property Assessed Clean Energy (“PACE”) Bonds.
  • The Class A Notes and Class B Notes (together, the “Notes”) are secured by a portfolio of PACE bonds (“PACE Bonds”) acquired by FortiFi 2023-1 (the “Issuer”) at closing (the “Initial PACE Bonds”) and during the Prefunding Period (the “Subsequent PACE Bonds” and together with the Initial PACE Bonds, the “PACE Bond Portfolio”).
  • The Initial PACE Bonds are secured by 5,025 PACE assessments levied against 5,007 residential properties and 18 commercial properties (“PACE Assessments”) in 41 Florida counties and 33 California counties.

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

Retrieved on: 
Wednesday, May 10, 2023

RESEARCH TRIANGLE PARK, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented preliminary results from 30 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate (ADC), sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). These data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab. As expected, patients with PD-L1(+) tumors appear to respond earlier than patients with PD-L1(-) tumors. The Company expects to reach the overall survival (OS) endpoints in the first quarter of 2024.

Key Points: 
  • These data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab.
  • The Company expects to reach the overall survival (OS) endpoints in the first quarter of 2024.
  • The poster, titled, “Trilaciclib Combined with Sacituzumab Govitecan (SG) In Metastatic Triple-Negative Breast Cancer (mTNBC): Preliminary Phase 2 Results,” can be found here .
  • (Includes TEAEs with a ≥ 10% increase with sacituzumab vs. chemotherapy)
    Phase 2 trial of trilaciclib in combination with sacituzumab: TRAEs (n=30)

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 4, 2023

We now expect to announce a recommended Phase 2 dose in early 2024, which provides us an opportunity to assess potential preliminary efficacy earlier than anticipated.

Key Points: 
  • We now expect to announce a recommended Phase 2 dose in early 2024, which provides us an opportunity to assess potential preliminary efficacy earlier than anticipated.
  • 2023 is shaping up to be a breakout year for Immuneering as we continue to expeditiously advance IMM-1-104 in the clinic.
  • Chief Business Officer appointed: In March 2023, the company announced the appointment of Harold E. Brakewood (“E.B.”) as its Chief Business Officer.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended 2023, were $10.2 million compared with $9.1 million for the first quarter of 2022.

New Research from Alegeus Finds Many Laid Off Employees Unfamiliar with Continuation of Health Coverage

Retrieved on: 
Thursday, May 4, 2023

COBRA provides continuing group health insurance coverage for employees and their families after a job loss or other qualifying event.

Key Points: 
  • COBRA provides continuing group health insurance coverage for employees and their families after a job loss or other qualifying event.
  • More than 185,000 employees across the country have been laid off to date in 2023 ( Layoffs.fyi ).
  • Employees rely heavily on their current health plans—Nearly half (47%) would be willing to pay a high premium to stay on their current plan.
  • A growing need for continuation of health coverage education—In addition to covering their COBRA costs, 33 percent of respondents feel their employer bears responsibility for explaining this coverage to them.

Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering

Retrieved on: 
Thursday, May 4, 2023

Mekonos, Inc. , a biotech platform company building the future of cell therapies on a chip, has announced a new research collaboration with bit.bio , a synthetic biology company providing human cells for research, drug discovery and cell therapy.

Key Points: 
  • Mekonos, Inc. , a biotech platform company building the future of cell therapies on a chip, has announced a new research collaboration with bit.bio , a synthetic biology company providing human cells for research, drug discovery and cell therapy.
  • Developing this approach as an alternative to viral vector delivery will enable bit.bio to precisely engineer stem cells into any mature, functional human cell type with higher efficiency, speed and control.
  • “The combination of Mekonos’ unique, silicon chip-based delivery platform with bit.bio’s leading cellular reprogramming technologies will enable powerful new levels of precision and efficiency in the engineering of iPSCs,” said Jake Lesnik, VP of Business Development at Mekonos.
  • “We are optimistic this collaboration will help unlock new opportunities for efficiency in the iPSC engineering process that further advance our cell therapy development.”
    Initial results stemming from the research collaboration are expected mid-year.

Osino Announces Filing of Amended and Restated Technical Report for Its Twin Hills Gold Project and Ondundu Gold Project, Namibia

Retrieved on: 
Friday, April 28, 2023

In addition, the Company also wishes to announce that it has filed its amended and restated technical report entitled, “Ondundu Gold Project, Namibia, Amended and Restated NI 43-101 Technical Report” dated effective October 7, 2022 and signed April 21, 2023 (the "Ondundu Technical Report") for its technical report announced in the Company's news release dated December 8, 2022, which amends and restates the technical report for the Ondundu Gold Project filed on December 8, 2022 (the "Previous Ondundu Report").

Key Points: 
  • In addition, the Company also wishes to announce that it has filed its amended and restated technical report entitled, “Ondundu Gold Project, Namibia, Amended and Restated NI 43-101 Technical Report” dated effective October 7, 2022 and signed April 21, 2023 (the "Ondundu Technical Report") for its technical report announced in the Company's news release dated December 8, 2022, which amends and restates the technical report for the Ondundu Gold Project filed on December 8, 2022 (the "Previous Ondundu Report").
  • The Ondundu Technical Report updates and replaces the Previous Ondundu Report to provide disclosure to more correctly meet the form requirements of NI 43-101.
  • There are no material changes to the PFS Technical Report or Ondundu Technical Report and their prior versions, other than to address form requirements under NI 43-101 which were discovered under the process of review in connection with the Company's preliminary short form base shelf prospectus.
  • For additional information, please refer to the PFS Technical Report and Ondundu Technical Report available on the Osino website and filed on SEDAR under the Company's profile at www.sedar.com, which is an update of the Initial PFS and contains the most current comprehensive technical information and reflects the Company's news release dated September 6, 2022.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of FIGS, and Opendoor on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 24, 2023

NEW YORK, April 23, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors FIGS, Inc. (NYSE: FIGS), and Opendoor Technologies, Inc. (NASDAQ: OPEN) on behalf of long-term stockholders.

Key Points: 
  • NEW YORK, April 23, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors FIGS, Inc. (NYSE: FIGS), and Opendoor Technologies, Inc. (NASDAQ: OPEN) on behalf of long-term stockholders.
  • Bragar Eagel & Squire is investigating certain officers and directors of FIGS, Inc. following a class action complaint that was filed against FIGS on December 8, 2022.
  • While FIGS is best known for its medical scrubs, it also offers other healthcare apparel including lab coats, outerwear, activewear, loungewear, compression socks, footwear, and masks.
  • Of those shares, FIGS sold 4,636,364 shares, and the remaining 25,707,953 shares were sold by Tulco, LLC (“Tulco”), the Company’s largest stockholder.

Gatos Silver Receives NYSE Notice Regarding 2022 10-K Filing

Retrieved on: 
Wednesday, April 19, 2023

In accordance with Section 802.01E of the NYSE Listed Company Manual, the NYSE will closely monitor the status of the Company’s late filing and related public disclosures for up to six months from the date of the filing delinquency (the “Initial Cure Period”).

Key Points: 
  • In accordance with Section 802.01E of the NYSE Listed Company Manual, the NYSE will closely monitor the status of the Company’s late filing and related public disclosures for up to six months from the date of the filing delinquency (the “Initial Cure Period”).
  • The Company’s common stock will continue to trade on the NYSE during the Initial Cure Period, subject to the Company’s compliance with other continued listing requirements.
  • Notwithstanding the foregoing, if circumstances warrant, the NYSE may commence delisting proceedings at any time.
  • The Company has also requested an extension of the time to file the 2022 Form 10-K under the policies of the Toronto Stock Exchange.

SCHULTZE SPECIAL PURPOSE ACQUISITION CORP. II ANNOUNCES EXPECTED CONVERSION OF CLASS B SHARES IN CONNECTION WITH PROPOSED EXTENSION

Retrieved on: 
Friday, March 31, 2023

If the Charter Amendment Proposal is approved at the Special Meeting, all holders of Class B common stock, par value $0.0001 per share, of the Company (“Class B Common Stock” and such holders, the “Initial Stockholders”) have agreed to convert all shares of Class B Common Stock to shares of Class A common stock, par value $0.0001 per share, of the Company (“Class A Common Stock”), on a one-for-one basis in accordance with the Company’s charter, upon the implementation of the Extension (collectively, the “Class B Conversion”).

Key Points: 
  • If the Charter Amendment Proposal is approved at the Special Meeting, all holders of Class B common stock, par value $0.0001 per share, of the Company (“Class B Common Stock” and such holders, the “Initial Stockholders”) have agreed to convert all shares of Class B Common Stock to shares of Class A common stock, par value $0.0001 per share, of the Company (“Class A Common Stock”), on a one-for-one basis in accordance with the Company’s charter, upon the implementation of the Extension (collectively, the “Class B Conversion”).
  • The Class B Conversion would be effected prior to the redemption of any public shares in connection with the implementation of the Extension and would result in an additional 4,125,000 shares of Class A Common Stock outstanding upon completion.
  • Notwithstanding the Class B Conversion, the Initial Stockholders will be not entitled to receive any funds held in the trust account with respect to any shares of Class A Common Stock issued to such holders as a result of the Class B Conversion.
  • The Company has not made any determination to liquidate the securities held in the trust account and, upon implementation of the Extension, intends to continue maintaining the funds held in the trust account in U.S. government treasury obligations or money market funds.

Leading Edge Materials CEO's Report fo the Shareholders

Retrieved on: 
Thursday, March 30, 2023

Stockholm, March 30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides a letter from the Chief Executive Officer.

Key Points: 
  • Stockholm, March 30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides a letter from the Chief Executive Officer.
  • Our vision, materials for change, is right in the middle of these societal challenges.
  • A change in the energy system towards renewables and energy storage, electrified mobility solutions and resilient and sustainable supply-chains will need new materials and new sources for those materials.
  • Graphite is a key material to enable the energy transition, where most lithium-ion battery chemistries use graphite for the anode.